Deferitrin

DB16132InvestigationalSmall molecule

Deferitrin is under investigation in clinical trial NCT00069862 (Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-thalassemia).

Mechanism: Pharmacologically active on Iron
Curator reviewed
Formula / weight: C₁₁H₁₁NO₄S · 253.27 g/mol (avg)
Code names: GT-56-252

Resolves to

Compound

UNIIT69Y9LDN44CAS239101-33-8ChEMBLCHEMBL432481

Structure

InChIKeyOEUUFNIKLCFNLN-LLVKDONJSA-NSMILESC[C@@]1(CSC(=N1)C1=CC=C(O)C=C1O)C(O)=O

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Deferitrin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account